Literature DB >> 27142625

No Need of Immediate Treatment for Hypovascular Tumors Associated with Hepatocellular Carcinoma.

Yutaka Midorikawa1, Tadatoshi Takayama2, Satoshi Nara3, Takuya Hashimoto4, Kiyohiko Omichi5, Kiyoko Ebisawa1, Tokio Higaki1, Shingo Tsuji6, Hirohiko Sakamoto5, Kazuaki Shimada3, Masatoshi Makuuchi4.   

Abstract

BACKGROUND: Hypovascular tumors associated with hepatocellular carcinoma (HCC) can be diagnosed, but it remains unknown whether such lesions should be treated immediately. This study aimed to clarify the clinical significance of treating hypovascular liver nodules.
METHODS: After diagnosis of hypovascular tumors smaller than 3 cm, 104 patients underwent liver resection immediately (Group 1), while 93 patients were placed under observation (Group 2). In Group 1, 98 patients were diagnosed as having HCC (Group 1'), while 80 patients in Group 2 underwent liver resection after vascularization or appearance of other hypervascular HCC (Group 2'), eight patients had been observed, and five patients could not undergo operation due to appearance of other multiple HCCs. To avoid lead time bias for tumor vascularization, survival rates of patients after diagnosis of hypovascular tumors as well as those after operation in the two groups were compared.
RESULTS: After a median follow-up of 3.3 years (range 0.6-11.2), the 5-year overall survival rates after liver resection of Group 1' (74.8 %; 95 % CI 64.3-86.1) was significantly higher than that of Group 2' (59.2 %; 46.4-75.6; P = 0.027). However, the 5-year overall survival rates after diagnosis of hypovascular liver nodules of Group 1' (74.7 %; 66.1-85.0) was not significantly different from that of Group 2' (77.1 %; 67.0-88.6; P = 0.761). Consequently, the 5-year overall survival rate after diagnosis of Group 2 (75.6 %; 64.7-83.1) was not significantly different from that of Group 1 (73.2 %; 67.5-86.1; P = 0.591) by intention-to-treat analysis.
CONCLUSIONS: It is not necessary to treat hypovascular liver tumors immediately after diagnosis.

Entities:  

Mesh:

Year:  2016        PMID: 27142625     DOI: 10.1007/s00268-016-3548-4

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  23 in total

Review 1.  Cancer screening.

Authors:  A Barratt; P Mannes; L Irwig; L Trevena; J Craig; L Rychetnik
Journal:  J Epidemiol Community Health       Date:  2002-12       Impact factor: 3.710

2.  Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium.

Authors:  M Hayashi; O Matsui; K Ueda; Y Kawamori; M Kadoya; J Yoshikawa; T Gabata; T Takashima; A Nonomura; Y Nakanuma
Journal:  AJR Am J Roentgenol       Date:  1999-04       Impact factor: 3.959

3.  Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach.

Authors:  Abbas Mourad; Sylvie Deuffic-Burban; Nathalie Ganne-Carrié; Thibaud Renaut-Vantroys; Isabelle Rosa; Anne-Marie Bouvier; Guy Launoy; Stephane Cattan; Alexandre Louvet; Sébastien Dharancy; Jean-Claude Trinchet; Yazdan Yazdanpanah; Philippe Mathurin
Journal:  Hepatology       Date:  2014-02-25       Impact factor: 17.425

4.  Is screening for breast cancer with mammography justifiable?

Authors:  P C Gøtzsche; O Olsen
Journal:  Lancet       Date:  2000-01-08       Impact factor: 79.321

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

6.  Imaging of multistep human hepatocarcinogenesis.

Authors:  Osamu Matsui; Tosifumi Gabata; Satoshi Kobayashi; Noboru Terayama; Junn-Ichiro Sanada; Wataru Kouda; Hiroko Kawashima
Journal:  Hepatol Res       Date:  2007-09       Impact factor: 4.288

7.  Early hepatocellular carcinoma as an entity with a high rate of surgical cure.

Authors:  T Takayama; M Makuuchi; S Hirohashi; M Sakamoto; J Yamamoto; K Shimada; T Kosuge; S Okada; K Takayasu; S Yamasaki
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

8.  Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm.

Authors:  Kenichi Takayasu; Shigeki Arii; Michiie Sakamoto; Yutaka Matsuyama; Masatoshi Kudo; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Namiki Izumi; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Liver Int       Date:  2013-02-28       Impact factor: 5.828

9.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  1 in total

Review 1.  Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology.

Authors: 
Journal:  Korean J Radiol       Date:  2017-04-03       Impact factor: 3.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.